Benzinga's Microcap Movers for Thursday May 24, 2012
Below are highlights from Benzinga's daily coverage of microcap securities making big moves:
Shares of Thwapr (THWI), the Las Vegas, NV mobile video sharing company, rose 75% Thursday on 23 times the average daily volume.
Thwapr signed an exclusive agreement with a leading marketing and branding company in Asia, Shyalala, to develop new business opportunities by introducing Thwapr as a new visual communication channel in Asia for brands and personalities to engage their communities.
Under the partnership, Shyalala will work closely with Thwapr to deliver a strategy for using Thwapr's proprietary mobile video sharing technology to build community engagement services. Shyalala will also leverage its business relationships and alliances to integrate Thwapr as part of its current offering. And Thwapr will provide technical support and the resources needed to service the Asia Pacific marketplace.
Thwapr closed at $0.042 on Thursday.
Shares of Complete Genomics (NASDAQ: GNOM), the Mountain View, CA human genome sequencing and analysis, rose 26.63% Thursday on 7 times the average daily volume.
Complete Genomics was one of several genome sequencing stocks that surged on Thursday on the heels of Rosetta Genomics (NASDAQ: ROSG), whose stock has made an amazing run since undergoing a 1:15 reverse split on May 15.
Complete Genomics closed at $2.33 on Thursday.
Shares of Vermillion (NASDAQ: VRML), the Austin, TX developer of diagnostic tests, rose 47.88% Thursday on 5 times the average daily volume.
A spokesperson for Vermillion said there was no news to account for the move, but did acknowledge it was most likely due to strength in the overall sector led by Rosetta Genomics.
Vermillion closed at $2.72 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.